Previous 10 | Next 10 |
Theravance Biopharma ( TBPH ) +14% to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B. TransGlobe Energy ( TGA ) +9% agrees to acquire TransGlobe Energy in all stock deal. Payoneer Global ( PAYO ) +8% . Marinus Pharm...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) is selling its rare pediatric disease Priority Review Voucher (PRV) for $110M. The Radnor, Pa.-based company had received the voucher when the U.S. Food and Drug Administration (FDA) approved its seizure treatment Ztalmy in M...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial ...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase 3 RAISE trial in refractory status epilepticus (RSE) to expand e...
The U.S.-based commercial-stage company Marinus Pharmaceuticals (NASDAQ:MRNS) announced on Wednesday that the European regulators agreed to the company’s request to allow additional four months to submit data for the review of its seizure candidate ganaxolone. In 2021, Marinus (MRNS) s...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June: Citi B...
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2022 Earnings Conference Call May 12, 2022, 04:00 PM ET Company Participants Sasha Damouni Ellis - VP, Corporate Communications, and IR Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Steve Pfanstiel - Chief Financial Offi...
Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q1 GAAP EPS of -$0.52 beats by $0.33. Revenue of $14.19M (+684.0% Y/Y) beats by $11.91M. For further details see: Marinus Pharmaceuticals GAAP EPS of -$0.52 beats by $0.33, revenue of $14.19M beats by $11.91M
ZTALMY ® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 Trust...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...